Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

The development of neutralizing antibodies can limit the therapeutic effectiveness of systemically administered oncolytic viruses (OV). Here, to enable repeated intravenous administration, the authors report the development of synthetic RNA viruses formulated within lipid nanoparticles, showing anti...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Edward M. Kennedy, Agnieszka Denslow, Jacqueline Hewett, Lingxin Kong, Ana De Almeida, Jeffrey D. Bryant, Jennifer S. Lee, Judy Jacques, Sonia Feau, Melissa Hayes, Elizabeth L. McMichael, Daniel Wambua, Terry Farkaly, Amal A Rahmeh, Lauren Herschelman, Danielle Douglas, Jacob Spinale, Sanmit Adhikari, Jessica Deterling, Matt Scott, Brian B. Haines, Mitchell H. Finer, Ted T Ashburn, Christophe Quéva, Lorena Lerner
Formaat: Artikel
Taal:English
Gepubliceerd in: Nature Portfolio 2022-10-01
Reeks:Nature Communications
Online toegang:https://doi.org/10.1038/s41467-022-33599-w

Internet

https://doi.org/10.1038/s41467-022-33599-w

Gelijkaardige items